<DOC>
	<DOCNO>NCT00471484</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , doxorubicin , fluorouracil , work different way stop growth tumor cell , either kill cell stop dividing . Interferon alfa may interfere growth tumor cell . Giving combination chemotherapy together interferon alfa may kill tumor cell . PURPOSE : This phase II trial study well give combination chemotherapy together interferon alfa-2b work treat patient nonmetastatic liver cancer remove surgery .</brief_summary>
	<brief_title>Combination Chemotherapy Interferon Alfa-2b Treating Patients With Nonmetastatic Liver Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient unresectable , nonmetastatic hepatocellular carcinoma treat neoadjuvant oxaliplatin , doxorubicin hydrochloride , fluorouracil , recombinant interferon alfa-2b . Secondary - Determine overall survival patient treat regimen . - Determine progression-free survival patient treat regimen . - Determine rate conversion resectability tumor patient treat regimen . - Determine toxicity profile regimen patient . - Assess quality life patient treat regimen . - Correlate change serological marker angiogenesis treatment clinical outcome patient . - Correlate validate use functional imaging treatment clinical outcome patient . OUTLINE : Patients receive neoadjuvant OXAFI therapy comprise oxaliplatin IV doxorubicin hydrochloride IV day 1 , 8 15 ; fluorouracil IV continuously day 1-28 ; recombinant interferon alfa-2b subcutaneously three time weekly week 1-4 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients receive least 2 course neoadjuvant therapy undergo evaluation response . Patients whose disease become resectable achieve complete partial response proceed surgery . Patients whose disease remain unresectable reevaluated disease either become resectable , complete neoadjuvant therapy , meet discontinuation criterion . At least 2 week receive neoadjuvant therapy , patient whose disease resectable undergo surgery potentially complete resection tumor curative intent . Patients achieve complete resection proceed adjuvant therapy . At least 4 week surgery , patient may restart OXAFI adjuvant therapy , provide fully recover surgery receive few 6 course neoadjuvant therapy . Adjuvant therapy repeat every 28 day total 6 course ( include neoadjuvant OXAFI ) absence disease progression unacceptable toxicity . Patients undergo blood tissue collection baseline periodically study evaluation circulate tissue biomarkers angiogenesis . Serum venous blood sample analyze concentration VEGF ELISA . Tumor tissue obtain treatment examined tumor VEGF expression , microvessel density , cellular proliferation IHC . Patients complete quality life questionnaire baseline , monthly study treatment , course 6 neoadjuvant chemotherapy , upon discontinuation study treatment . Patients follow periodically 5 year curative resection tumor . PROJECTED ACCRUAL : A total 54 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm hepatocellular carcinoma Advanced , unresectable , nonmetastatic disease Multifocal disease within lobe liver allow Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan No intractable ascites control medical therapy No extrahepatic metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month WBC ≥ 3,000/mm³ ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Bilirubin ≤ 2.9 mg/dL AST ALT ≤ 5 time upper reference range ( URR ) Albumin &gt; 30 g/L Creatinine ≤ 1.5 time URR Creatinine clearance &gt; 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study therapy No prior malignancy except nonmelanoma skin cancer carcinoma situ cervix No concurrent substantial medical illness , cardiac renal disease MUGA heart study normal No history allergic reaction attribute compound similar chemical biological composition use study No history autoimmune disease No thyroid dysfunction No active hepatitis B C flare chronic active hepatitis Hepatitis B surface antigen ( HBsAg ) status know If HBsAg negative , antiHBc antibody test ; antiHBc positive , hepatitis B virus ( HBV ) DNA detection perform discern presence mutant HBV carriage No alcohol drug abuse No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia No psychiatric illness social situation would preclude study compliance Patients history depression psychiatric disorder ineligible PRIOR CONCURRENT THERAPY : No prior chemotherapy and/or radiotherapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>childhood hepatocellular carcinoma</keyword>
	<keyword>stage III childhood liver cancer</keyword>
	<keyword>stage IV childhood liver cancer</keyword>
</DOC>